Related Experiment Video
Updated: Apr 30, 2026
10:42
Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics
Published on: June 17, 2022
3.1K
Exploring the transition to DRGs in Developing Countries: A case study in Shanghai, China
Zhaoxin Wang1, Rui Liu2, Ping Li3
1Zhaoxin Wang, Shanghai Tenth People's Hospital, Tongji University School of Medicine, China.
Pakistan Journal of Medical Sciences
|April 29, 2014
Summary
Diagnosis Related Groups (DRGs) implementation in China faces challenges. Key patient factors like age and length of stay, along with hospital economic level, significantly impact costs for hypertension and heart disease, guiding payment reform.
Area of Science:
- Health Economics
- Healthcare Management
- Public Health Policy
Background:
- Diagnosis Related Groups (DRGs) payment system adoption in China since 2004 has faced significant implementation challenges.
- Bridging the gap between traditional pay-for-service models and DRGs is crucial for China's ongoing healthcare payment reform.
Purpose of the Study:
- To investigate factors influencing inpatient medical expenses in China during the transition to DRGs.
- To inform the development of effective DRGs pricing standards by identifying key cost determinants.
Main Methods:
- Prospective study of 22,130 patients with hypertension or coronary heart disease across 60 Shanghai hospitals (2008-2012).
- Hospitals categorized by economic level; patients sampled randomly within morbidity ranks.
- Multiple linear regression analysis to examine relationships between medical expenses and patient/hospital characteristics (age, gender, length of stay, region, economic level).
Main Results:
- Age, length of stay (LOS), and hospital economic level significantly impacted total medical expenses for both hypertension and coronary heart disease patients.
- Gender was a significant factor only for coronary heart disease patients.
- Recommendations for developing countries: prioritize common diseases and analyze key cost-affecting factors.
Conclusions:
- Simplifying DRGs standard-setting through standardized clinical pathways and accurate costing is vital for effective implementation in developing countries.
- Tailoring DRGs pricing to include factors like age, LOS, economic level, and gender (for specific conditions) can improve system efficiency.
Related Concept Videos
01:28Global Regulatory Systems
959
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
959
01:03Drug Control Governance: Regulatory Bodies and Their Impact
706
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
706